Clinical Trial Detail

NCT ID NCT03003676
Title A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Targovax Oy
Indications

melanoma

Therapies

Cyclophosphamide + ONCOS-102 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.